

Reference:	FOI.9564.22
Subject:	Dermatological conditions
Date of Request:	4 August 2022

Requested:

- How many patients were treated in last 4 months by the Dermatology department (for any disease) with each of the following:
 - Abrocitinib
 - Acitretin
 - Alitretinoin
 - Azathioprine
 - Baricitinib
 - Ciclosporin
 - Dupilumab
 - Methotrexate
 - Mycophenolate mofetil
 - Pimecrolimus
 - Tacrolimus ointment
 - Tralokinumab
 - Upadacitinib
- Of the patients treated in the last 4 months with any of the products listed in Q1, how many patients were paediatric (age 17 or under)?
- How many patients were treated in the last 4 months with phototherapy (UVB or PUVA) for atopic dermatitis ONLY?

Response:

- Hywel Dda University Health Board (UHB) provides, within the table below, the number of patients treated in the Dermatology Department with the listed medications, for any condition, during the period 1 April to 31 July 2022.

Medication	Number
Abrocitinib	0
Acitretin	61
Alitretinoin	*
Azathioprine	14
Baricitinib	0
Ciclosporin	9
Dupilumab	45
Methotrexate	33
Mycophenolate mofetil	*
Pimecrolimus	0
Tacrolimus ointment	*
Tralokinumab	0
Upadacitinib	*

Where the figures in the table have been replaced with an asterisk (*), the UHB is unable to provide you with the exact number of patients, due to the low number of cases (5 and under), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the Freedom of information Act 2000 (FoIA).

This information is protected by the Data Protection Act 2018 and the UK General Data Protection Regulations (UK GDPR), as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles 6 and 9 of the UK GDPR. This exemption is absolute and therefore, there is no requirement to apply the public interest test.

In reaching this decision, the Data Protection Act 2018/UK GDPR define personal data as data which relates to a living individual who can be identified solely from that data, or from that data and other information, which is in the possession of the data controller.

2. The UHB confirms that six (6) patients under the age of seventeen (17) were prescribed the medications listed, during the period 1 April to 31 July 2022.
3. The UHB confirms that no patients were treated with phototherapy (UVB or PUVA) for atopic dermatitis only, during the period 1 April to 31 July 2022.